|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Margalit O, Mamtani R, Yang YX, Reiss KA,
Golan T, Halpern N, Aderka D, Giantonio B, Shacham-Shmueli E and
Boursi B: Assessing the prognostic value of carcinoembryonic
antigen levels in stage I and II colon cancer. Eur J Cancer.
94:1–5. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kannarkatt J, Joseph J, Kurniali PC,
Al-Janadi A and Hrinczenko B: Adjuvant Chemotherapy for Stage II
Colon Cancer: A Clinical Dilemma. J Oncol Pract. 13:233–241. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gold P and Freedman SO: Demonstration of
tumor-specific antigens in human colonic carcinomata by
immunological tolerance and absorption techniques. J Exp Med.
121:439–462. 1965. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Takagawa R, Fujii S, Ohta M, Nagano Y,
Kunisaki C, Yamagishi S, Osada S, Ichikawa Y and Shimada H:
Preoperative serum carcinoembryonic antigen level as a predictive
factor of recurrence after curative resection of colorectal cancer.
Ann Surg Oncol. 15:3433–3439. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Araujo RL, Gönen M, Allen P, DeMatteo R,
Kingham P, Jarnagin W, D'Angelica M and Fong Y: Positive
postoperative CEA is a strong predictor of recurrence for patients
after resection for colorectal liver metastases. Ann Surg Oncol.
22:3087–3093. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Konishi T, Shimada Y, Hsu M, Tufts L,
Jimenez-Rodriguez R, Cercek A, Yaeger R, Saltz L, Smith JJ, Nash
GM, et al: Association of preoperative and postoperative serum
carcinoembryonic antigen and colon cancer outcome. JAMA Oncol.
4:309–315. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Auclin E, André T, Taieb J, Banzi M, Van
Laethem JL, Tabernero J, Hickish T, de Gramont A and Vernerey D:
Association of post-operative CEA with survival and oxaliplatin
benefit in patients with stage II colon cancer: A post hoc analysis
of the MOSAIC trial. Br J Cancer. 121:312–317. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Benson AB III, Schrag D, Somerfield MR,
Cohen AM, Figueredo AT, Flynn PJ, Krzyzanowska MK, Maroun J,
McAllister P, Van Cutsem E, et al: American Society of Clinical
Oncology recommendations on adjuvant chemotherapy for stage II
colon cancer. J Clin Oncol. 22:3408–3419. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Labianca R, Nordlinger B, Beretta GD,
Mosconi S, Mandalà M, Cervantes A and Arnold D; ESMO Guidelines
Working Group, : Early colon cancer: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 24
(Suppl 6):vi64–vi72. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
National Comprehensive Cancer Network, .
Colon Cancer (Version 2.2017). https://www2.tri-kobe.org/nccn/guideline/colorectal/english/colon.pdfAugust
25–2020
|
|
12
|
Tsai HL, Huang CW, Chen CW, Yeh YS, Ma CJ
and Wang JY: Survival in resected stage II colorectal cancer is
dependent on tumor depth, vascular invasion, postoperative CEA
level, and the number of examined lymph nodes. World J Surg.
40:1002–1009. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Akaike H: Information theory and an
extension of the maximum likelihood principle. 2nd International
Symposium on Information Theory, Tsahkadsor, Armenia, USSR,
September 2–8, 1971. Petrov BN and Caski F: Akadémiai Kiadó;
Budapest: pp. 267–281. 1973
|
|
14
|
Kim CW, Yoon YS, Park IJ, Lim SB, Yu CS
and Kim JC: Elevation of preoperative s-CEA concentration in stage
IIA colorectal cancer can also be a high risk factor for stage II
patients. Ann Surg Oncol. 20:2914–2920. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lin JK, Lin CC, Yang SH, Wang HS, Jiang
JK, Lan YT, Lin TC, Li AF, Chen WS and Chang SC: Early
postoperative CEA level is a better prognostic indicator than is
preoperative CEA level in predicting prognosis of patients with
curable colorectal cancer. Int J Colorectal Dis. 26:1135–1141.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Akagi T and Inomata M: Essential advances
in surgical and adjuvant therapies for colorectal cancer 2018–2019.
Ann Gastroenterol Surg. 4:39–46. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gelibter AJ, Caponnetto S, Urbano F,
Emiliani A, Scagnoli S, Sirgiovanni G, Napoli VM and Cortesi E:
Adjuvant chemotherapy in resected colon cancer: When, how and how
long? Surg Oncol. 30:100–107. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Matsuda T, Yamashita K, Hasegawa H,
Oshikiri T, Hosono M, Higashino N, Yamamoto M, Matsuda Y, Kanaji S,
Nakamura T, et al: Recent updates in the surgical treatment of
colorectal cancer. Ann Gastroenterol Surg. 2:129–136. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Peach G, Kim C, Zacharakis E, Purkayastha
S and Ziprin P: Prognostic significance of circulating tumour cells
following surgical resection of colorectal cancers: A systematic
review. Br J Cancer. 102:1327–1334. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu CY, Uen YH, Tsai HL, Chuang SC, Hou MF,
Wu DC, Juo SH, Lin SR and Wang JY: Molecular detection of
persistent postoperative circulating tumour cells in stages II and
III colon cancer patients via multiple blood sampling: Prognostic
significance of detection for early relapse. Br J Cancer.
104:1178–1184. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lecomte T, Berger A, Zinzindohoué F,
Micard S, Landi B, Blons H, Beaune P, Cugnenc PH and Laurent-Puig
P: Detection of free-circulating tumor-associated DNA in plasma of
colorectal cancer patients and its association with prognosis. Int
J Cancer. 100:542–548. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tie J, Wang Y, Tomasetti C, Li L, Springer
S, Kinde I, Silliman N, Tacey M, Wong HL, Christie M, et al:
Circulating tumor DNA analysis detects minimal residual disease and
predicts recurrence in patients with stage II colon cancer. Sci
Transl Med. 8:346ra922016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yakabe T, Nakafusa Y, Sumi K, Miyoshi A,
Kitajima Y, Sato S, Noshiro H and Miyazaki K: Clinical significance
of CEA and CA19-9 in postoperative follow-up of colorectal cancer.
Ann Surg Oncol. 17:2349–2356. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Burdy G, Panis Y, Alves A, Nemeth J,
Lavergne-Slove A and Valleur P: Identifying patients with T3-T4
node-negative colon cancer at high risk of recurrence. Dis Colon
Rectum. 44:1682–1688. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Freedman LS: Tables of the number of
patients required in clinical trials using the logrank test. Stat
Med. 1:121–129. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Biagi JJ, Raphael MJ, Mackillop WJ, Kong
W, King WD and Booth CM: Association between time to initiation of
adjuvant chemotherapy and survival in colorectal cancer: A
systematic review and meta-analysis. JAMA. 305:2335–2342. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Des Guetz G, Nicolas P, Perret GY, Morere
JF and Uzzan B: Does delaying adjuvant chemotherapy after curative
surgery for colorectal cancer impair survival? A meta-analysis. Eur
J Cancer. 46:1049–1055. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Alexander JC, Silverman NA and Chretien
PB: Effect of age and cigarette smoking on carcinoembryonic antigen
levels. JAMA. 235:1975–1979. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Clinical practice guidelines for the use
of tumor markers in breast and colorectal cancer. Adopted on May
17, 1996 by the American Society of Clinical Oncology. J Clin
Oncol. 14:2843–2877. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Litvak A, Cercek A, Segal N, Reidy-Lagunes
D, Stadler ZK, Yaeger RD, Kemeny NE, Weiser MR, Pessin MS and Saltz
L: False-positive elevations of carcinoembryonic antigen in
patients with a history of resected colorectal cancer. J Natl Compr
Canc Netw. 12:907–913. 2014. View Article : Google Scholar : PubMed/NCBI
|
